Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Genzyme Gains Breakthrough Designation for Rare Disease Drug

By Drug Discovery Trends Editor | June 5, 2015

The Food and Drug Administration (FDA) has granted Genzyme a breakthrough therapy designation for a drug called olipudase alfa, an enzyme-replacement therapy intended for the treatment of Niemann-Pick Disease Type B (NPB) otherwise known as acid sphingomyelinase deficiency.

Genzyme touted the label in a statement,explaining that this life-threatening disease occurs when there is, “insufficient activity of the enzyme acid sphingomyelinase (ASM), which results in toxic accumulation of sphingomyelin.”

An inability to metabolize sphingomyelin, along with a buildup of the lipid within the cell,s can lead to cell death and malfunctioning of major organ systems, according to the company’s announcement. 

Olipudase alfa is being designed to address the underlying cause of NPB and serve as a substitute for the missing enzyme so the body can breakdown the sphingomyelin. There are currently no approved treatments for this disorder. 

FierceBiotech reports the FDA decided to give the tag to Genzyme after five patients demonstrated early signs of efficacy in a Phase 1b trial. 

A breakthrough therapy designation will help Genzyme quickly move through the rest of the regulatory process. 

Meanwhile, the drugmaker has begun enrollment for a Phase 1/2 pediatric study of olipudase alfa and is preparing to launch a Phase 2/3 adult study in the second half of 2015.

READ MORE: AbbVie Receives Breakthrough Designation for Cancer Drug


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE